Trials / Completed
CompletedNCT04800224
Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2)
The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- D'Or Institute for Research and Education · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Among candidate adjunct treatment options, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties.
Detailed description
To evaluate the efficacy and safety of oral propolis as an adjunct treatment for SARS-CoV-2 infection, we designed a randomized, double-blind, placebo-controlled trial (Bee-Covid2) (The Use of Brazilian Green Propolis Extract (EPP-AF®) in Patients Affected by COVID-19).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Standardized Brazilian Green Propolis Extract | 900mg/day of Standardized Brazilian Green Propolis Extract for 10 days. |
| DRUG | Placebo | 900mg/day of Placebo for 10 days. |
Timeline
- Start date
- 2021-04-12
- Primary completion
- 2021-07-30
- Completion
- 2021-07-30
- First posted
- 2021-03-16
- Last updated
- 2022-05-13
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT04800224. Inclusion in this directory is not an endorsement.